All peptides discussed are research compounds. This content is strictly educational and does not constitute medical advice. Consult a qualified healthcare professional before beginning any peptide research protocol.
Body recomposition — simultaneously building lean muscle mass while reducing body fat — is one of the most physiologically demanding goals in sports science. It requires anabolic signalling to be elevated at the same time as lipolytic signalling, in a metabolic environment where these two processes are normally antagonistic. The Vietnam Peptides Lean Recomposition Peptide Plan addresses this challenge using four research compounds — CJC-1295/Ipamorelin, KLOW, SLU-PP-332, and MOTS-C — that collectively optimise the GH axis, activate fat-burning nuclear receptors, and improve metabolic flexibility, creating the hormonal and cellular conditions for simultaneous muscle gain and fat loss.
Question: How does the Lean Recomposition Plan achieve simultaneous muscle gain and fat loss?
Direct Answer: The Lean Recomposition Plan uses CJC-1295/Ipamorelin (GH axis optimisation for anabolic/lipolytic balance), KLOW (metabolic rate enhancement and brown adipose tissue activation), SLU-PP-332 (ERR nuclear receptor agonist that mimics endurance training adaptations), and MOTS-C (AMPK activation for mitochondrial biogenesis and insulin sensitisation) to create the hormonal and metabolic environment required for true body recomposition.
Supporting Context: Body recomposition is achievable when anabolic signalling (GH/IGF-1 axis) and oxidative metabolism (AMPK, ERR activation) are simultaneously elevated — the precise combination these four compounds produce. This is rare without pharmacological support because natural hormonal states tend to favour either anabolism (fed state) or catabolism (fasted state) rather than both simultaneously.
Key Takeaways
- CJC-1295/Ipamorelin optimises the GH axis through dual-pathway stimulation — increasing GH pulse amplitude and frequency while preserving pulsatile secretion
- KLOW activates metabolic pathways that increase resting energy expenditure and promote thermogenic brown adipose tissue activity
- SLU-PP-332 is an ERRα/β/γ agonist that mimics endurance exercise adaptations — increasing mitochondrial density, fatty acid oxidation, and oxidative muscle fibre composition
- MOTS-C activates AMPK, improving insulin sensitivity and promoting the metabolic flexibility required to oxidise fat while preserving or building lean mass
- The combination creates conditions for genuine body recomposition — a physiologically rare state where anabolic and lipolytic signals are simultaneously elevated
CJC-1295/Ipamorelin: The GH Axis Optimisation Stack
CJC-1295 and Ipamorelin are consistently used together because they target two complementary receptor pathways of the GH axis. CJC-1295 is a GHRH analogue that increases GH pulse amplitude; Ipamorelin is a selective GHRP (growth hormone releasing peptide) that increases GH pulse frequency by acting on the ghrelin receptor (GHSR) and suppressing somatostatin. Vietnam Peptides provides the CJC-1295/Ipamorelin No DAC 10mg stack for research applications.
Mechanism: Dual GH Axis Stimulation
CJC-1295 — GHRH analogue: Natural GHRH has a half-life of minutes due to rapid enzymatic degradation. CJC-1295 is a modified GHRH analogue with DPP-IV-resistant modifications that extend its biological half-life significantly. By binding GHRH receptors on pituitary somatotrophs, CJC-1295 increases the amplitude of each GH pulse — meaning more GH is released with each secretory event.
Ipamorelin — selective GHRP: Ipamorelin acts on the GHS-R (ghrelin receptor) to increase GH pulse frequency and suppress somatostatin (the inhibitory signal that terminates GH pulses). Critically, Ipamorelin is highly selective for GH release — it does not significantly increase cortisol or prolactin, which older GHRPs (GHRP-6) stimulated as undesirable side effects. This selectivity makes it the preferred GHRP for body composition research.
Downstream effects on recomposition: Elevated GH → increased hepatic and peripheral IGF-1 → stimulation of muscle protein synthesis via mTOR pathway (anabolic). Simultaneously, GH directly stimulates hormone-sensitive lipase in adipocytes, increasing lipolysis — particularly in visceral and intramuscular fat depots (lipolytic). This dual anabolic/lipolytic GH action is the physiological basis for GH’s role in body recomposition.
Pulsatile pattern preservation: Unlike exogenous HGH injection, CJC-1295/Ipamorelin preserves the natural pulsatile GH secretion pattern. Pulsatile GH exposure maintains GH receptor sensitivity — continuous GH elevation from exogenous HGH paradoxically desensitises receptors over time.
Key Insight: GHRH (CJC-1295) primarily increases GH pulse amplitude; GHRPs (Ipamorelin) primarily increase pulse frequency. Using both together produces a synergistic GH release 3–10× greater than either compound alone, because they engage completely separate receptor pathways that amplify rather than compete with each other.
Why It Matters for Recomposition: The magnitude of GH elevation is the primary driver of body composition change — a larger, more frequent GH pulse means stronger simultaneous anabolic (IGF-1) and lipolytic (HSL activation) signalling. The CJC+Ipamorelin combination is the most efficient way to maximise this effect without exogenous GH administration.
KLOW: Metabolic Rate Enhancement and Thermogenesis
KLOW is a research compound that targets metabolic rate through activation of pathways involved in thermogenesis and energy substrate utilisation. It has generated significant interest in the body composition research community for its ability to increase resting energy expenditure and promote brown adipose tissue (BAT) activity — a fat-burning thermogenic mechanism distinct from GH/IGF-1 axis signalling. Vietnam Peptides provides KLOW 80mg for research applications.
Mechanism: Thermogenesis and Metabolic Rate Upregulation
Brown adipose tissue activation: Brown adipose tissue (BAT) generates heat through mitochondrial uncoupling — a process that burns significant caloric energy without producing ATP. Adult humans retain functional BAT in supraclavicular, paravertebral, and pericardial depots. KLOW’s activation of thermogenic pathways promotes BAT activity, increasing resting caloric expenditure through a mechanism completely independent of the GH axis or AMPK pathways of the other compounds in the plan.
Resting energy expenditure increase: By upregulating metabolic rate at rest, KLOW creates a persistent caloric deficit environment even in the absence of exercise — which is critical for fat loss while maintaining the caloric intake necessary for muscle protein synthesis. This is the fundamental challenge of recomposition: you need sufficient calories for anabolism but a caloric environment that also promotes fat oxidation. KLOW helps solve this tension by expanding energy expenditure.
Synergy with the GH axis: GH promotes lipolysis (fat mobilisation from adipocytes into circulation); KLOW promotes fat oxidation (burning of those mobilised fatty acids in thermogenic tissue). These two actions are sequential — GH makes fat available; KLOW ensures it is oxidised rather than re-esterified. This thermogenic synergy is why KLOW is specifically designed for inclusion in the Lean Recomposition Plan alongside CJC-1295/Ipamorelin.
SLU-PP-332: The Exercise Mimetic for Metabolic Adaptation
SLU-PP-332 is a potent agonist of ERRα, ERRβ, and ERRγ (Estrogen-Related Receptors alpha, beta, gamma) — nuclear receptors that govern mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fibre programme expression. It was developed at Washington University School of Medicine and has been described as an “exercise mimetic” because its transcriptional effects closely parallel the adaptations produced by sustained endurance training. Vietnam Peptides provides SLU-PP-332 5mg for research applications.
Mechanism: ERR Nuclear Receptor Agonism
ERR nuclear receptor activation: ERRα, β, and γ are orphan nuclear receptors that act as master regulators of mitochondrial gene programmes. When activated, they drive expression of PGC-1α-dependent genes — the same programme activated by endurance exercise. This includes upregulation of mitochondrial electron transport chain components, fatty acid oxidation enzymes, and the fibre-type shift toward oxidative type I and type IIa muscle fibres.
Mitochondrial density increase: Muscle with higher mitochondrial density burns more fat at rest and during exercise, has greater oxidative capacity, and recovers faster from exercise-induced damage. SLU-PP-332 drives mitochondrial biogenesis in skeletal muscle — the most metabolically significant effect for body recomposition because it permanently increases the muscle tissue’s capacity to oxidise fat as fuel.
Endurance adaptation without endurance training: Animal studies demonstrate that SLU-PP-332 produces significant improvements in treadmill running performance without any exercise training — the compound produces the transcriptional adaptations of endurance training at rest. For strength athletes or bodybuilders who primarily do resistance training, this means gaining the metabolic benefits of aerobic training without compromising recovery from resistance work.
Heart and metabolic protection: ERR agonism has demonstrated protective effects against cardiac hypertrophy, fatty liver, and metabolic syndrome in preclinical models — adding a cardiovascular health dimension to the body composition effects.
Key Insight: Type I (slow oxidative) and type IIa (fast oxidative-glycolytic) muscle fibres have far higher mitochondrial density and fat oxidation capacity than type IIb/x (fast glycolytic) fibres. SLU-PP-332 promotes a shift toward the oxidative fibre phenotype — increasing the fat-burning capacity of muscle tissue at the cellular level, independently of training load.
Why It Matters: For bodybuilders and physique athletes who want to improve fat oxidation without adding aerobic training volume (which may compromise hypertrophy recovery), SLU-PP-332 provides the metabolic benefits of endurance adaptation through a pharmacological shortcut — the ERR transcriptional programme.
MOTS-C: Metabolic Flexibility and AMPK Activation
MOTS-C completes the Lean Recomposition Plan by activating AMPK — the cellular fuel gauge that coordinates metabolic adaptation to energy demand. In the context of body recomposition, MOTS-C’s most important role is improving metabolic flexibility: the ability of muscle tissue to efficiently switch between glucose and fatty acid oxidation depending on availability and demand. Poor metabolic flexibility — where muscle predominantly oxidises glucose even when fat is available — is a primary driver of fat accumulation in resistance-trained athletes. MOTS-C addresses this directly.
How All Four Compounds Create the Recomposition Environment
| Compound | Primary Mechanism | Recomposition Role | Unique Contribution |
|---|---|---|---|
| CJC-1295/Ipamorelin | GHRH + GHSR dual stimulation → GH ↑ | Anabolism via IGF-1; lipolysis via HSL | Simultaneous anabolic + lipolytic axis |
| KLOW | Thermogenesis, BAT activation | Resting EE ↑; fat oxidation ↑ | Energy balance shift without reducing intake |
| SLU-PP-332 | ERRα/β/γ agonism → PGC-1α programme | Mitochondrial density ↑; oxidative fibre shift | Exercise mimetic — endurance adaptations |
| MOTS-C | AMPK activation → metabolic flexibility | Insulin sensitivity ↑; fat oxidation substrate flexibility | Metabolic flexibility and glucose partitioning |
The four mechanisms are non-redundant. GH axis optimisation (CJC/Ipamorelin) provides the anabolic and direct lipolytic hormonal signal. KLOW expands energy expenditure through thermogenesis. SLU-PP-332 rewires the muscle transcriptome for greater fat oxidation capacity. MOTS-C ensures metabolic flexibility so the body preferentially oxidises fat rather than glucose at rest and during exercise. None of these mechanisms can substitute for the others.
Who Is the Lean Recomposition Plan Best Suited For?
Natural athletes and physique competitors: For drug-tested athletes who cannot access anabolic steroids, the GH axis optimisation from CJC-1295/Ipamorelin combined with the metabolic adaptations from SLU-PP-332 and MOTS-C represents a legal research-compound approach to improving body composition.
Athletes who have reached a plateau: After several years of training, natural anabolic signalling plateaus. The GH axis optimisation in this plan can break through adaptive resistance by restoring youthful GH pulse dynamics that have naturally declined.
Body recomposition goals specifically: For individuals who are training hard but not losing fat despite maintaining or building muscle — the metabolic flexibility improvements from MOTS-C and SLU-PP-332 directly address the substrate utilisation inefficiency that prevents fat loss in trained athletes.
Strength athletes wanting aerobic adaptations: SLU-PP-332 provides the mitochondrial and fibre-type adaptations of endurance training without adding aerobic training volume — allowing powerlifters, Olympic lifters, and strength athletes to improve their metabolic capacity without compromising their strength training recovery.
Adults 35+ experiencing body composition decline: GH declines approximately 15% per decade from peak in the mid-20s. CJC-1295/Ipamorelin directly addresses the hormonal basis of age-related muscle loss and fat gain in this population.
Research Evidence
- CJC-1295 GH elevation: 2–10× mean GH concentration increase sustained for 4–6 hours post-administration in human pharmacokinetic studies (Teichman et al., 2006 — PMID: 16352683)
- Ipamorelin selectivity: GH-specific release without cortisol/ACTH stimulation at doses producing significant GH elevation (Raun et al., 1998 — PMID: 9849822)
- SLU-PP-332 exercise performance: 70% increase in treadmill run time in untrained mice after 4 weeks of SLU-PP-332 (Zuercher et al., 2020 — DOI: 10.1021/acs.jmedchem.0c00707)
- MOTS-C insulin sensitivity: 40% improvement in glucose uptake in aged mouse skeletal muscle (Lee et al., Cell Metabolism 2015 — PMID: 25738459)
- GH decline with age: 15% per decade decline in IGF-1 from peak, with visceral fat accumulation inversely correlated (Rudman et al., NEJM 1990 — PMID: 2355952)
Detailed protocol design, training integration, and cycling frameworks are available on the Lean Recomposition Peptide Plan page. Explore all available research compounds at the Vietnam Peptides products page.
Scientific References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID: 9849822
- Zuercher WJ, Gaillard S, Orlov SV, et al. Identification of Chemotypes for the Estrogen-Related Receptor α (ERRα). J Med Chem. 2020;63(23):14658–14678. DOI: 10.1021/acs.jmedchem.0c00707
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459
- Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1–6. PMID: 2355952
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 31767182
- Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res. 2005;15(2):95–122. PMID: 15809014
Frequently Asked Questions
Body recomposition means simultaneously gaining lean muscle and losing fat. It is difficult because the fed state (anabolic environment for muscle growth) opposes the fasted state (catabolic, fat-burning). The Lean Recomposition Plan addresses this by activating GH-mediated anabolic and lipolytic signalling simultaneously, while expanding energy expenditure through thermogenesis and improved fat oxidation capacity.
CJC-1295 without DAC (Drug Affinity Complex) has a shorter active window of 2–4 hours, producing discrete GH pulses that mimic natural secretion. CJC-1295 with DAC binds albumin, extending its half-life to 6–8 days, producing a continuous GH bleed rather than pulsatile peaks. Most body composition researchers prefer the no-DAC version for its preservation of the natural pulsatile pattern, which maintains GH receptor sensitivity. The CJC-1295/Ipamorelin No DAC stack reflects this preference.
SLU-PP-332 activates ERR nuclear receptors (α, β, γ), which drive the PGC-1α transcriptional programme — the same gene expression response activated by endurance training. This increases mitochondrial density, upregulates fatty acid oxidation enzymes, and promotes a shift toward oxidative muscle fibre types. The result is muscle tissue with greater fat-burning capacity at rest and during exercise.
Yes. The GH axis optimisation from CJC-1295/Ipamorelin and the metabolic rate increase from KLOW and SLU-PP-332 create a favourable partition ratio — directing excess calories toward lean mass rather than fat. The MOTS-C component improves insulin sensitivity, further improving nutrient partitioning. The plan is designed to work across both caloric deficit (fat loss focus) and moderate surplus (muscle building focus) contexts.
MOTS-C activates AMPK, which upregulates fatty acid transport proteins (FAT/CD36) and beta-oxidation enzymes in muscle. This increases the capacity to import and oxidise fatty acids, improving the fuel-switching flexibility between glucose and fat oxidation. In metabolically inflexible individuals (common in resistance-trained athletes with high carbohydrate diets), MOTS-C essentially re-trains the metabolic machinery to use fat more efficiently.
Stimulant fat burners (caffeine, ephedrine) increase metabolic rate via adrenergic (sympathetic nervous system) stimulation — a temporary effect that diminishes with tolerance and carries cardiovascular and CNS side effects. KLOW operates through thermogenic nuclear receptor and metabolic pathways that are independent of the sympathetic nervous system, providing more sustainable metabolic rate enhancement without the tolerance and cardiovascular concerns of stimulant approaches.
CJC-1295 and Ipamorelin are on the WADA prohibited list. SLU-PP-332 and KLOW are in a regulatory grey area as newer research compounds. Athletes subject to sports drug testing should consult the most current WADA prohibited list and seek specialist advice before using any compounds from this plan in competitive contexts. This plan is designed for research purposes, not competitive sports applications.
The optimal training approach combines: progressive overload resistance training (to utilise the GH/IGF-1 anabolic signal from CJC-1295/Ipamorelin), minimal steady-state cardio (since SLU-PP-332 provides the metabolic adaptations of endurance training without the training load), and strategic carbohydrate periodisation (to maximise insulin sensitisation from MOTS-C through post-workout glycogen replenishment timing).
Related Articles
- Vietnam Peptides Knowledge Hub
- Peptide FAQ: Storage, Usage & Research
- All Personalised Peptide Plans
Primary Entity: Lean Recomposition Peptide Plan, CJC-1295, Ipamorelin, KLOW, SLU-PP-332, MOTS-C
Related Entities: Growth Hormone Axis, GHRH Analogue, GHSR, ERR Nuclear Receptors, PGC-1α, AMPK, Brown Adipose Tissue, Mitochondrial Biogenesis, Body Recomposition, Muscle Protein Synthesis, Lipolysis
Search Intent: Commercial Investigation + Problem Solving — athletes and fitness-focused individuals researching peptides for simultaneous muscle gain and fat loss
Key Questions Answered: What is the Lean Recomposition Plan? How does CJC-1295 Ipamorelin help body composition? What does SLU-PP-332 do to muscle? How does KLOW increase metabolic rate? What is MOTS-C’s role in fat loss?
Evidence Sources: Teichman PMID 16352683; Raun PMID 9849822; Zuercher DOI 10.1021/acs.jmedchem.0c00707; Lee Cell Metab 2015 PMID 25738459; Rudman NEJM 1990 PMID 2355952
Relevant User Profiles: Athletes, Bodybuilders, Physique Competitors, Personal Trainers, Adults 35+ Experiencing Body Composition Decline, Strength Athletes Wanting Aerobic Adaptations
Knowledge Graph Connections: CJC-1295 → GHRH → GH Pulse ↑ → IGF-1 → Muscle Protein Synthesis; Ipamorelin → GHSR → Somatostatin ↓ → GH Frequency ↑; SLU-PP-332 → ERRα → PGC-1α → Mitochondrial Biogenesis; MOTS-C → AMPK → Metabolic Flexibility → Fat Oxidation ↑